Phase IV Protocol Submissions Should Not Have Time Limits, Merck Tells FDA
Executive Summary
FDA should not impose time limits on submission of protocols for postmarketing studies, Merck's comments on FDA's draft guidance on postmarketing study status reports say.
You may also be interested in...
ClinicalTrials.gov Oversteps Corporate Confidentiality Protections – Merck
The trial information required for the ClinicalTrials.gov database undermines corporate confidentiality protections, Merck maintained in comments to HHS' Committee on Regulatory Reform
ClinicalTrials.gov Oversteps Corporate Confidentiality Protections – Merck
The trial information required for the ClinicalTrials.gov database undermines corporate confidentiality protections, Merck maintained in comments to HHS' Committee on Regulatory Reform
Phase IV Commitments Should Be Enforced By Civil Penalties, Not Withdrawal
FDA expects to propose civil monetary penalties as one enforcement option for companies failing to fulfill postmarketing commitments, in lieu of removing the drug from the market.